Abstract
Drug therapy for symptomatic multiple myeloma is comparable for both sexes in its effectiveness and safety. A 3-year event-free survival is comparable in men and women; overall survival in men is lower than in women.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Disease-Free Survival
-
Female
-
Humans
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / mortality
-
Sex Factors
-
Time Factors
-
Treatment Outcome